Pei Yang

List of Publications by Year
in descending order

30 papers	1,565 citations	471371 17 h-index	477173 29 g-index
33 all docs	33 docs citations	33 times ranked	2006 citing authors

#	Article	IF	Citations
1	CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	3.2	448
2	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	3.2	194
3	Management and survival rates in patients with glioma in China (2004â€“2010): a retrospective study from a single-institution. Journal of Neuro-Oncology, 2013, 113, 259-266.	1.4	144
4	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget, 2015, 6, 40896-40906.	0.8	116
5	Classification based on mutations ofTERTpromoter andIDHcharacterizes subtypes in grade II/III gliomas. Neuro-Oncology, 2016, 18, 1099-1108.	0.6	93
6	Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance. PLoS ONE, 2015, 10, e0126022.	1.1	59
7	MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget, 2014, 5, 12908-12915.	0.8	54
8	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget, 2016, 7, 16384-16395.	0.8	53
9	Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. Oncotarget, 2015, 6, 18105-18115.	0.8	48
10	Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget, 2015, 6, 7318-7324.	0.8	40
11	Correlation of preoperative seizures with clinicopathological factors and prognosis in anaplastic gliomas: A report of 198 patients from China. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 844-851.	0.9	39
12	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget, 2015, 6, 36643-36651.	0.8	39
13	Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget, 2014, 5, 12593-12606.	0.8	36
14	Clinicopathological factors predictive of postoperative seizures in patients with gliomas. Seizure: the Journal of the British Epilepsy Association, 2016, 35, 93-99.	0.9	31
15	ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion. PLoS ONE, 2015, 10, e0142856.	1.1	28
16	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. Oncotarget, 2015, 6, 11676-11682.	0.8	28
17	Classifying lower grade glioma cases according to whole genome gene expression. Oncotarget, 2016, 7, 74031-74042.	0.8	27
18	Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. Journal of Neurosurgery, 2017, 126, 249-259.	0.9	19

#	Article	IF	Citations
19	Prognostic value of a nine-gene signature in glioma patients based on tumor-associated macrophages expression profiling. Clinical Immunology, 2020, 216, 108430.	1.4	18
20	Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. Oncotarget, 2016, 7, 45005-45014.	0.8	10
21	Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. Oncotarget, 2017, 8, 42974-42982.	0.8	8
22	Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. Cancer Immunology, Immunotherapy, 2021, 70, 2589-2600.	2.0	5
23	High expression of VAT1 is a prognostic biomarker and predicts malignancy in glioblastoma. Oncology Reports, 2019, 42, 1422-1430.	1.2	5
24	Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults. Neuro-Oncology Advances, 2020, 2, vdaa098.	0.4	4
25	A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level. Journal of Cancer Research and Clinical Oncology, 2020, 146, 579-591.	1.2	4
26	Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. Oncotarget, 2016, 7, 80091-80100.	0.8	2
27	Predicting the likelihood of postoperative seizure status based on mRNA sequencing in low-grade gliomas. Future Oncology, 2018, 14, 545-552.	1.1	1
28	Integrated analysis of the genomic and transcriptional profile of high-grade gliomas in different age groups. Clinical Immunology, 2021, 226, 108719.	1.4	1
29	A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma. BioMed Research International, 2022, 2022, 1-21.	0.9	1
30	Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma. Chinese Neurosurgical Journal, 2022, 8, 6.	0.3	0